{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:20:08Z","timestamp":1783455608604,"version":"3.55.0"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:title>Graphical Abstract<\/jats:title><jats:p\/>","DOI":"10.3389\/fcvm.2021.713694","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:56:06Z","timestamp":1634356566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission"],"prefix":"10.3389","volume":"8","author":[{"given":"Andrea","family":"Montisci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Donatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-80-2-249","article-title":"A new anticancer drug with significant clinical activity","volume":"80","author":"Blum","year":"1974","journal-title":"Ann Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II beta-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.bjc.6601904","article-title":"Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy","volume":"91","author":"Pein","year":"2004","journal-title":"Br J Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ajhg.2019.04.017","article-title":"Estimating the effectiveness of DPYD genotyping in italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity","volume":"104","author":"Fragoulakis","year":"2019","journal-title":"Am J Hum Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity -Ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-019-0048-3","article-title":"5-FU induced cardiotoxicity: case series and review of the literature","volume":"5","author":"Yuan","year":"2019","journal-title":"Cardiooncology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"257.e1","DOI":"10.1016\/j.ajem.2010.10.025","article-title":"Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis","volume":"30","author":"\u00c7alik","year":"2012","journal-title":"Am J Emerg Med."},{"key":"B17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C","article-title":"The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy","volume":"71","author":"Robben","year":"1993","journal-title":"Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem."},{"key":"B19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0002-8703(87)90517-5","article-title":"5-Fluorouracil-induced coronary vasospasm","volume":"114","author":"Burger","year":"1987","journal-title":"Am Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1161\/01.RES.54.6.711","article-title":"Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys","volume":"54","author":"Heistad","year":"1984","journal-title":"Circ Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/01.CIR.79.3.698","article-title":"Effect of early and advanced atherosclerosis on vascular responses to serotonin, thromboxane A2, and ADP","volume":"79","author":"Lopez","year":"1989","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1172\/JCI109858","article-title":"Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism","volume":"66","author":"Henry","year":"1980","journal-title":"J Clin Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/sca.4950230101","article-title":"Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation","volume":"23","author":"Kinhult","year":"2001","journal-title":"Scanning."},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s001250051162","article-title":"Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation","volume":"42","author":"Schalkwijk","year":"1999","journal-title":"Diabetologia."},{"key":"B27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.7326\/0003-4819-80-4-531","article-title":"Cyclophosphamide: use in practice","volume":"80","author":"Gershwin","year":"1974","journal-title":"Ann Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1016\/j.bmc.2014.02.035","article-title":"Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function","volume":"22","author":"Field","year":"2014","journal-title":"Bioorg Med Chem."},{"key":"B29","first-page":"3360","article-title":"A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer","volume":"8","author":"Giordano","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","article-title":"Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy","volume":"11","author":"Gianni","year":"2005","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2020.03.007","article-title":"Precision medicine in distinct heart failure phenotypes: focus on clinical epigenetics","volume":"224","author":"Napoli","year":"2020","journal-title":"Am Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa054504","article-title":"HER2 and responsiveness of breast cancer to adjuvant chemotherapy","volume":"354","author":"Pritchard","year":"2006","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13148-021-01047-z","article-title":"Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside","volume":"13","author":"Sarno","year":"2021","journal-title":"Clin Epigenetics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst."},{"key":"B38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"B39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10549-012-2189-z","article-title":"Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence","volume":"135","author":"Valachis","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapys (neo) adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J Clin Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am J Physiol Cell Physiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/jat.2813","article-title":"Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome","volume":"32","author":"Yang","year":"2012","journal-title":"J Appl Toxicol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/08977194.2020.1825410","article-title":"Useful applications of growth factors for cardiovascular regenerative medicine","volume":"38","author":"De Pascale","year":"2020","journal-title":"Growth Factors."},{"key":"B44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11936-014-0335-0","article-title":"Recognizing and managing leftventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway","volume":"16","author":"Groarke","year":"2014","journal-title":"CurrTreat Options Cardiovasc Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation."},{"key":"B46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1161\/CIRCRESAHA.108.178467","article-title":"An ezrin\/calpain\/PI3K\/AMPK\/ eNOSs1179 signaling cascade mediating VEGFdependent endothelial nitric oxide production","volume":"104","author":"Youn","year":"2009","journal-title":"Circ Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11906-011-0206-y","article-title":"Mechanisms of antiangiogenicinduced arterial hypertension","volume":"13","author":"Mourad","year":"2011","journal-title":"Curr Hypertens Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/annonc\/mdp417","article-title":"Reversibility of capillary density after discontinuation of bevacizumab treatment","volume":"21","author":"Steeghs","year":"2010","journal-title":"Ann Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All antivascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome': a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11936-016-0452-z","article-title":"Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options","volume":"18","author":"Brinda","year":"2016","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail."},{"key":"B52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5603\/AIT.2014.0056","article-title":"Ten good reasons to practice ultrasound in critical care","volume":"46","author":"Lichtenstein","year":"2014","journal-title":"Anaesthesiol Intensive Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/eurheartj\/ehv510","article-title":"Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure","volume":"37","author":"Maja","year":"2016","journal-title":"Eur Heart J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr."},{"key":"B57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jcmg.2018.03.025","article-title":"Contemporary role of echocardiography for clinical decision making in patients during and after cancer therapy","volume":"11","author":"Liu","year":"2018","journal-title":"JACC Cardiovasc Imaging."},{"key":"B59","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1016\/j.ejca.2013.06.046","article-title":"Left ventricular systolic function in HER2\/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of leftventricular ejection fraction and myocardial strain imaging over 12 months","volume":"49","author":"Stoodley","year":"2013","journal-title":"Eur J Cancer."},{"key":"B61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr."},{"key":"B62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/HCO.0000000000000541","article-title":"Applications of left ventricular strain measurements to patients undergoing chemotherapy","volume":"33","author":"Clasen","year":"2018","journal-title":"Curr Opin Cardiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.echo.2012.09.001","article-title":"Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know?","volume":"25","author":"Oreto","year":"2012","journal-title":"J Am Soc Echocardiogr."},{"key":"B64","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0735-1097(92)90138-D","article-title":"Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans","volume":"20","author":"Stoddard","year":"1992","journal-title":"J Am Coll Cardiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.euje.2005.04.009","article-title":"Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study","volume":"7","author":"Tassan-Mangina","year":"2006","journal-title":"Eur J Echocardiogr."},{"key":"B66","first-page":"857","article-title":"Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy","volume":"62","author":"Mason","year":"1978","journal-title":"Cancer Treat Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/ejechocard\/jer142","article-title":"Assessment of right ventricular functions during cancer chemotherapy","volume":"12","author":"Tanindi","year":"2011","journal-title":"Eur J Echocardiogr."},{"key":"B68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.hfc.2019.12.002","article-title":"Acute decompensated heart failure in patients with heart failure with preserved ejection fraction","volume":"16","author":"Sugimoto","year":"2020","journal-title":"Heart Fail Clin."},{"key":"B69","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1540-8175.2008.00705.x","article-title":"Echocardiographic predictors of change in left ventricular diastolic pressure in heart failure patients receiving nesiritide","volume":"25","author":"Weeks","year":"2008","journal-title":"Echocardiography."},{"key":"B70","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1540-8175.2005.40076.x","article-title":"Accuracy of tissue Doppler echocardiography in the emergency diagnosis of decompensated heart failure with preserved left ventricular systolic function: comparison with B-type natriuretic peptide measurement","volume":"22","author":"Arques","year":"2005","journal-title":"Echocardiography."},{"key":"B71","first-page":"327","article-title":"Bedside lung ultrasound in the care of the critically ill","volume":"19","author":"Rudas","year":"2017","journal-title":"Crit Care Resusc."},{"key":"B72","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jccase.2018.06.001","article-title":"Assessment of myocardial fibrosis using T1-mapping and extracellular volume measurement on cardiac magnetic resonance imaging for the diagnosis of radiation-induced cardiomyopathy","volume":"18","author":"Mukai-Yatagai","year":"2018","journal-title":"J Cardiol Cases."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e013755","DOI":"10.1161\/JAHA.119.013755","article-title":"Multimodality cardiac imaging in the era of emerging cancer therapies","volume":"9","author":"Biersmith","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B74","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/euhj.2001.3038","article-title":"Assessment of myocardial viability by cardiovascular magnetic resonance imaging","volume":"23","author":"Mahrholdt","year":"2002","journal-title":"Eur Heart J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/01.CIR.0000118493.13323.81","article-title":"Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology","volume":"109","author":"Mahrholdt","year":"2004","journal-title":"Circulation."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0210909","DOI":"10.1371\/journal.pone.0210909","article-title":"Evidence of association of circulating epigenetic-sensitive biomarkers with suspected coronary heart disease evaluated by cardiac computed tomography","volume":"14","author":"Infante","year":"2019","journal-title":"PLoS ONE."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa072100","article-title":"Coronary calcium as a predictor of coronary events in four racial or ethnic groups","volume":"358","author":"Detrano","year":"2008","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis","volume":"21","author":"Osborne","year":"2014","journal-title":"J Nucl Cardiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B81","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/jclinpath-2019-206178","article-title":"Fluid-based assays and precision medicine of cardiovascular diseases: the 'hope' for Pandora's box?","volume":"72","author":"Benincasa","year":"2019","journal-title":"J Clin Pathol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa0805299","article-title":"A sensitive cardiac troponin T assay in stable coronary artery disease","volume":"361","author":"Omland","year":"2009","journal-title":"N Engl J Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B87","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clon.2019.11.008","article-title":"Dynamic changes in high-sensitivity cardiac troponin i in response to anthracycline-based chemotherapy","volume":"32","author":"Tzolos","year":"2020","journal-title":"Clin Oncol."},{"key":"B88","first-page":"266","article-title":"Left ventricular systolic dysfunction predicted by early troponin I release after anthracycline based chemotherapy in breast cancer patients","volume":"29","author":"Shafi","year":"2017","journal-title":"J Ayub Med College Abbottabad."},{"key":"B89","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.2016-0289","article-title":"Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin","volume":"22","author":"Olivieri","year":"2017","journal-title":"Oncologist."},{"key":"B90","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am College Cardiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The Role of Biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J Cardiovasc Transl Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cca.2014.12.011","article-title":"Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines","volume":"441","author":"Pourier","year":"2015","journal-title":"Clinica Chimica Acta."},{"key":"B94","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/apa.12862","article-title":"Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines","volume":"104","author":"Yl\u00e4nen","year":"2015","journal-title":"Acta Paediatrica."},{"key":"B95","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2710.2004.00556.x","article-title":"Influence of high-dose leucovorin and 5- fluorouracil chemotherapy regimen on P wave duration and dispersion","volume":"29","author":"Ceyhan","year":"2004","journal-title":"J Clin Phar. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0003319716637516","article-title":"Usefulness of heart-type fatty acid-binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity","volume":"68","author":"Turan","year":"2017","journal-title":"Angiology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Oztop","year":"2004","journal-title":"Jpn J Clin Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s12032-009-9226-8","article-title":"5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels","volume":"27","author":"Salepci","year":"2010","journal-title":"Med Oncol"},{"key":"B99","first-page":"1883","article-title":"Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients\u2013a pilot study","volume":"27","author":"Holubec","year":"2007","journal-title":"Anticancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10637-010-9546-8","article-title":"Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials","volume":"30","author":"Ederhy","year":"2012","journal-title":"Invest New Drugs."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00392-007-0633-6","article-title":"Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults","volume":"97","author":"Dodos","year":"2008","journal-title":"Clin Res Cardiol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1007\/s13277-015-4183-7","article-title":"Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients","volume":"37","author":"De Iuliis","year":"2016","journal-title":"Tumor Biol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J Cardiac Fail."},{"key":"B106","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.breast.2015.10.004","article-title":"Brain natriuretic peptide as a cardiac marker of transient radiotherapy related damage in left-sided breast cancer patients: a prospective study","volume":"25","author":"Palumbo","year":"2016","journal-title":"Breast"},{"key":"B108","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1158\/1078-0432.CCR-10-1359","article-title":"Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dosedense chemotherapy incorporating trastuzumab and lapatinib","volume":"17","author":"Morris","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","article-title":"The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II\u2013positive breast cancer treated with adjuvant trastuzumab therapy","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am College Cardiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-012-2039-z","article-title":"High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study","volume":"134","author":"Onitilo","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1373\/clinchem.2009.142257","article-title":"Use of myeloperoxidase for risk stratification in acute heart failure","volume":"56","author":"Reichlin","year":"2010","journal-title":"Clin Chem."},{"key":"B115","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cam4.430","article-title":"Intensive care admission of cancer patients: a comparative analysis","volume":"4","author":"Bos","year":"2015","journal-title":"Cancer Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3322\/caac.21351","article-title":"Critical care of patients with cancer","volume":"66","author":"Shimabukuro-Vornhagen","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s00134-017-4884-z","article-title":"The intensive care medicine research agenda on critically ill oncology and hematology patients","volume":"43","author":"Azoulay","year":"2017","journal-title":"Intensive Care Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.bja.2020.06.060","article-title":"Epigenetic susceptibility to severe respiratory viral infections and its therapeutic implications: a narrative review","volume":"125","author":"Crimi","year":"2020","journal-title":"Br J Anaesth."},{"key":"B119","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/ejhf.646","article-title":"Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012","volume":"19","author":"Puymirat","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1097\/TXD.0000000000001172","article-title":"Veno-arterial extracorporeal membrane oxygenation as bridge to heart transplantation: the way forward","volume":"7","author":"Montisci","year":"2021","journal-title":"Transplant Direct."},{"key":"B121","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer."},{"key":"B122","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/europace\/eum033","article-title":"Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator","volume":"9","author":"Rudzinski","year":"2007","journal-title":"Europace."},{"key":"B124","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/CIRCRESAHA.119.313577","article-title":"Anthracycline and peripartum cardiomyopathies","volume":"124","author":"Cowgill","year":"2019","journal-title":"Circ Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res Treat."},{"key":"B129","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-017-3712-8","article-title":"Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report","volume":"17","author":"Minichillo","year":"2017","journal-title":"BMC Cancer."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation."},{"key":"B131","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest."},{"key":"B132","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International expert consensus document on takotsubo syndrome (part i): clinical characteristics, diagnostic criteria, and pathophysiology","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J."},{"key":"B135","first-page":"627","article-title":"Heart transplantation in patients with malignant disease","volume":"9","author":"Armitage","year":"1990","journal-title":"J Heart Transplant."},{"key":"B136","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0002-9149(99)80704-8","article-title":"Orthotopic heart transplantation in patients with treated malignancies","volume":"75","author":"Goldstein","year":"1995","journal-title":"Am J Cardiol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/0959-8049(96)00028-7","article-title":"Cardiac transplanta- tion in childhood cancer survivors in Great Britain","author":"Levitt","year":"1996","journal-title":"Eur J Cancer."},{"key":"B138","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0002-9149(97)00031-3","article-title":"Results of heart transplantation in patients with pre- existing malignancies","volume":"79","author":"Koerner","year":"1997","journal-title":"Am J Cardiol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1097\/00007890-200005270-00025","article-title":"Cardiac transplantation in survivors of lymphoma: a multi- institutional survey","volume":"69","author":"Taylor","year":"2000","journal-title":"Transplantation."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.transproceed.2010.08.012","article-title":"Long-term outcome in heart transplant patients with pretransplant malignancies","volume":"42","author":"Fern\u00e1ndez-Vivancos","year":"2010","journal-title":"Transplant Proc."},{"key":"B141","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.healun.2012.03.018","article-title":"Characteristics and survival of patients with chemotherapy- induced cardiomyopathy undergoing heart transplantation","volume":"31","author":"Oliveira","year":"2012","journal-title":"J Heart Lung Transplant."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.healun.2012.09.018","article-title":"Outcomes of adults with restric- tive cardiomyopathy after heart transplantation","volume":"31","author":"DePasquale","year":"2012","journal-title":"J Heart Lung Transplant."},{"key":"B143","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.amjcard.2012.10.048","article-title":"Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy","volume":"111","author":"Lenneman","year":"2013","journal-title":"Am J Cardiol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCHEARTFAILURE.114.001292","article-title":"Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy","volume":"7","author":"Oliveira","year":"2014","journal-title":"Circ Heart Fail."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-018-0029-y","article-title":"Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure","volume":"4","author":"Araujo-Gutierrez","year":"2018","journal-title":"Cardiooncology."},{"key":"B146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40959-019-0042-9","article-title":"Takotsubo cardiomyopathy in cancer patients","volume":"5","author":"Desai","year":"2019","journal-title":"Cardiooncology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B148","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","article-title":"Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS registry (interagency registry for mechanically assisted circulatory support)","volume":"63","author":"Oliveira","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ehf2.12758","article-title":"Impella 5.0 supported oncological surgery as bridge to LVAD","volume":"8","author":"Montisci","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B150","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ejcts\/ezz098","article-title":"2019 EACTS Expert Consensus on long-term mechanical circulatory support","volume":"56","author":"Potapov","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.713694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:56:14Z","timestamp":1634356574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.713694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":151,"alternative-id":["10.3389\/fcvm.2021.713694"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.713694","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"article-number":"713694"}}